The question – “What diet should I follow?” – has perhaps never been more confusing, more controversial, or more stressful. There are more diets, diet books, diet opinions, and news headlines than ever before. In reality, no single “diet” trumps them all, especially for people with diabetes.
Modern life, with its preponderance of inadequate exposure to natural light during the day and overexposure to artificial light at night, is not conducive to the body’s natural sleep/wake cycle. It’s an emerging topic in health, one that UConn Health (University of Connecticut, Farmington, Conn.) cancer epidemiologist Richard Stevens has been studying for three decades.
Glyxambi combines empagliflozin, a sodium glucose cotransporter-2 inhibitor that blocks the absorption of excess glucose by the kidneys so it is released through urine, and linagliptin, a DPP-4 inhibitor that increases the production of insulin by the beta cells of the pancreas while reducing the amount of glucose produced by the liver.
According to a T1D Exchange article, researchers presented positive results in clinical trials of a new glucagon nasal powder at the Advanced Technologies & Treatments Diabetes conference in Paris, France.
If you have type 2 diabetes and find yourself struggling to stick to your daily medication regiment, there may be a new long-term drug delivery system hitting the market.
This was the finding of a comprehensive analysis of clinical trials covering more than 95,000 patients reported in The Lancet Diabetes and Endocrinology. The study was also presented at the 64th Annual Scientific Session of the American College of Cardiology in San Diego, CA, earlier this week.
In their annual report, the Diabetes Research Institute Foundation recently highlighted their Top 6 research breakthroughs in 2014.
Doctors at Joslin Diabetes Center think America’s emerging healthcare system will greatly benefit those with complex, chronic disorders like type 1 diabetes.
Missing just 30 minutes of sleep per day could negatively impact blood sugar control, according to researchers from Weill Cornell Medical College.
For the last year, Apple has been the 800-pound gorilla in mobile and wireless health. Stakeholders in the mobile health marketplace have been anxiously watching and speculating about what Apple would ultimately offer with its HealthKit platform and smartwatch.
We recently shared news about a new MIT study that used mice models to test an injectable “smart insulin.” This insulin activates only when there are traces of excess glucose in the bloodstream, an innovation which could potentially eliminate or lower the risk of hypoglycemia.
For months, the diabetes community has been speculating about the watch’s capabilities and what the HealthKit platform could do for daily diabetes self-care. Some have even hoped the watch would be able to monitor blood glucose readings without bloodletting, although there is no indication it is designed for this.
You are standing in your kitchen staring blankly, hands shaky, vision blurry, feeling confused and panicked as you try to decide what to eat or drink. You proceed to consume everything in sight as fast as humanly possible to treat the low.
“We want to make it easy for everyone to be able to help anyone who uses insulin anywhere, anytime,” says Locemia co-creator and chairman Robert Oringer, an entrepreneur with a long history in the diabetes industry.
Diabetics in the study who ate big breakfasts and small dinners had fewer episodes of high blood sugar than those who ate small breakfasts and large dinners, researchers found.
A recent study published in the Annals of Internal Medicine found that increased fiber consumption provided the same results as the standard dietary recommendations provided by the American Heart Association (AHA) for treating metabolic syndrome.
February may be a shorter month, but that doesn’t mean our Diabetes Online Community (DOC) was short of amazing content. There was a lot of love in the AroundDOCFebruaryair as usual this Valentine’s month, and unfortunately a lot of snow for our friends in much of the Eastern part of the U.S. Here are the […]
Sanofi, which has been bracing for increased competition for Lantus, has won the race to bring a new basal insulin to the marketplace. This week, the drug manufacturer announced the FDA has approved Toujeo, its new once-daily long-acting basal insulin. The new insulin is expected to go on sale in the U.S. by the start […]
We’ve barely begun 2015, but early returns suggest it’s going to be a banner year for diabetes technology. Here are some breakthroughs we’ve noted in the first two months (click on links to the full articles).
People who have low levels of vitamin D are more likely to have diabetes, regardless of how much they weigh, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.